Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Introduction of Retorovirus
- Disease derived from Retorovirus
- Discovery of ATL disease entity
- HTLV-1 discovery and world-wide distribution
- Gallo meeting, Kyoto (12.01.03)
- Cloning of IL-2 receptor alpha chain
- Discovery of ATL-derived factor (ADF)
- ADF is the human thioredoxin (TRX)
- Regulation of thioredoxin gene expression
- TRX transgenic and knock-out mice
- Survival and influenza resistance of TRX TG mice
- The thioredoxin system
- Thioredoxin superfamily
- IgE binding factor, GIF/MIF and TRX
- ADF peptide sequence A and B
- Dualistic function of MIF/GIF
- Inhibition of MIF expression by exogenous rhTRX
- Reciprocal regulation of TRX and GIF/MIF
- TRX1/ADF as an endogenous inhibitor of MIF/GIF
- Modulation of inflammation and cell death by TRX
- Modified TRX1 rapidly enters into cells (1)
- Modified TRX1 rapidly enters into cells (2)
- Raft fractionation of TRX-C35S-expressing cells
- rTRX-C35S interanalization is competed by wtTRX
- Lipid raft-mediated TRX transfer into cells
- rTRX suppresses bleomycin-induced lung injury
- Therapeutic effect of rTRX against lung disease
- Resistance against allergic inflammation/COPD
- Attenuation of Indomethacin-induced gastric ulcer
- Influenza virus infection resistance
- Possible aplication of rTRX in respiratory infections
- Thioredoxin binding proteins
- TBP-2 - a TRX binding protein
- TBP-2: tumor suppressor for HTLV-I leukemia
- TBP-2 knock-out and transgenic mice
- Thiol-dependent redox regulatory network update
- Clinical trials involving rTRX
- Redox research, International Redox Network
Topics Covered
- Life cycle of retroviruses
- Diseases derived from retroviruses
- Adult T-cell leukemia and HTLV-1 retrovirus
- ADF/TRX upregulation in HTLV-I T-cell and EBV B-cell transformation
- Regulation of thioredoxin gene expression
- TRX TG and KO mice
- The thioredoxin system
- MIF/GIF
- Inflammatory response
- TBP2: tumor suppressor for HTLV-I leukemia
- Clinical trials for inflammatory diseases
Talk Citation
Yodoi, J. (2007, October 1). The discovery of ATL field expansion in 40 yrs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/MKAK9648.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Junji Yodoi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.